-
-
Overview
-
Please contact us at for specific academic pricing.
Background
LY2334737 is an oral prodrug of gemcitabine, the clinically efficacious anticancer agent [1].LY2334737 has been shown the hydrolytic activity by carboxylesterase 2 (CES2). The Michaelis-Menten kinetic parameters are exhibited to be : Km of 43μM and Vmax of 40nmol/min/mg protein. In addition, LY2334737 has been found to be cytotoxic to cells in the NCl-60 panel with the EC50 values of 0.512±0.016μM, 0.402±0.018μM and 0.034±0.002μM for PC-GFP alone, HCT-116 mock transfectant and HCT-116 CES2 transfectant cell lines, respectively. Apart from these, the study result has been noted that parental SK-OV-3 cells were approximately 4-fold more sensitive to LY2334737 cytotoxicity than the SK-OV-3 knockdown with the EC50 values of 1.1μM and 4.5μM, respectively [1].
[1] Pratt SE1, Durland-Busbice S, Shepard RL, Heinz-Taheny K, Iversen PW, Dantzig AH. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells. Clin Cancer Res. 2013 Mar 1;19(5):1159-68.
-
- Properties
-
Overview